ClinicalTrials.gg
CompletedNCT01389284VERNEUpdated Aug 25, 2015Results posted

Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium

A Phase 3 interventional study of Naproxen Sodium ER (BAYH6689) and Naproxen Sodium IR (Aleve, BAYH6689) in Pain, Postoperative, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-25.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies testing naproxen in Pain, Postoperative — 2 open to participants now, 2 under way, 1 of them phase 3. Naproxen · Pain, Postoperative.

Enrollment
5th of 13
300 · median 200
Started
2011
with 1 other
Phase 3
5 of 13
1 open now
Registered
3rd of 13
by date
Lead sponsor
5 of 13
Bayer

Among the 13 studies testing naproxen in Pain, Postoperative, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 3rd registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,240 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 13 studies testing naproxen in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 675 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 328 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 15 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing naproxen in Pain, Postoperative, or all of them as a file.
02

Study summary

The objective is to evaluate pain relief of the extended release naproxen sodium 660 mg tablet compared to commercial naproxen sodium 220 mg tablet over 24 hours in patients with postsurgical dental pain.

03

Conditions studied

  • Pain, Postoperative

Keywords

  • Naproxen Sodium,
  • dental pain
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, male and female volunteers 15 years of age and above
  • Scheduled to undergo surgical removal of up to two impacted third molars, one of which must be mandibular full or partial bony impaction and the other a maxillary impaction
  • Female subjects of must be using a medically acceptable form of for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, NuvaRing, Depo-Provera, or double-barrier and have a negative pregnancy test at Screening and prior to surgery
  • Have not taken any form of medication or herbal supplements (ie, St. Johns Wort) within 5 days of admission (except for oral contraceptives, prophylactic antibiotics, or other routine medications to treat benign conditions, such as antibiotics to treat acne) and agree not to take any medication (other than that provided to them) throughout the study
  • Have not consumed alcoholic beverages, or foods and beverages containing xanthines (examples, coffee, tea, chocolate, and colas) after midnight prior to surgery and agree not to consume any of these foods or beverages throughout the evaluation period
  • Use of only short-acting local anesthetic (e.g., mepivacaine or lidocaine) preoperatively, with or without vasoconstrictor and nitrous oxide
  • Have moderate to severe postoperative pain on the Categorical Pain Intensity Scale (a score of at least 2 on a 4 point scale) and a score of ≥ 50 mm on the 100 mm Visual Analog Scale (VAS) within 4 hours postsurgery, but no later than 1330 hours +/- 15 minutes
  • Understand the pain rating scales (as judged by the study coordinator)
  • Be willing and able to participate in all scheduled visits, treatment plan, tests and other trial procedures according to the protocol
  • Provide a personally signed and dated form (ICF) indicating that the subject has been informed of all pertinent aspects of the trial, (subjects \< 18 years of age must sign a written assent and have parental or guardian consent)

Exclusion criteria

Exclusion Criteria:

  • History of to naproxen sodium, acetaminophen, Non Steroidal Anti-inflammatory Drugs (NSAIDS), aspirin, hydrocodone, similar pharmacological agents or components of the products
  • Evidence or history of (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or within the last 5 years
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study in the judgment of the investigator
  • Current or past history of gastrointestinal bleeding or other bleeding disorder(s)
  • Acute illness or local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator
  • Use of any Over-the-Counter (OTC) or prescription medications with which the administration of naproxen, acetaminophen, ibuprofen or any other NSAIDs, Lortab, is or use of any medications within 5 days of surgery (except oral , prophylactic antibiotics or medications to treat benign conditions such as antibiotics to treat acne)
  • Females who are pregnant or lactating
  • Habituation to analgesic drugs (i.e., routine use of oral analgesics 5 or more times per week for greater than 3 weeks)
  • Alcoholism or drug abuse within 2 years prior to the Screening Visit or routine consumption of 3 or more alcohol containing beverages per day
  • Positive urine, alcohol or nicotine test on day of surgery
  • Smokers or using nicotine replacement therapies including transdermal patches, spray, lozenges or gum
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Naproxen Sodium ER (BAYH6689)

    1 naproxen sodium extended release (ER) 660 mg tablet and 1 naproxen sodium immediate release (IR) 220 mg placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)

    Drug: Naproxen Sodium ER (BAYH6689) · Drug: Naproxen Sodium IR Placebo

  • Active comparator
    Naproxen Sodium IR (Aleve, BAYH6689)

    1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg tablet initially followed by 1 naproxen sodium IR 220 mg tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg tablet eight hours at hour 16 (± 15 min)

    Drug: Naproxen Sodium IR (Aleve, BAYH6689) · Drug: Naproxen Sodium ER Placebo

  • Placebo comparator
    Placebo

    1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg matching placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)

    Drug: Naproxen Sodium ER Placebo · Drug: Naproxen Sodium IR Placebo

Interventions

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours

  • DrugNaproxen Sodium ER Placebo

    Matching placebo of 660 mg Naproxen Sodium ER for 24 hours

  • DrugNaproxen Sodium IR Placebo

    Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours

06

What researchers measure

Primary outcomes

  1. Summed, Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24)

    SPID0-24 was calculated by multiplying the pain intensity difference score at each post-dose timepoint by the duration (in hours) since the preceding timepoint and then summing these values over 0 to 24 hours. Pain intensity was measured at baseline, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours using the 4-point categorical pain intensity scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. SPID0-24 can vary from -24 to 72. The positive SPID value indicates improvement of pain relief. The higher the SPID value, the more improvement of pain relief.

    Time frame: From 0 to 24 hours post-dose

Secondary outcomes

  1. Summed, Time-weighted Pain Intensity Differences (SPID)

    Pain intensity was measured at baseline, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours using the 4-point categorical pain intensity scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total possible score ranges of SPIDs are SPID0-6: -6 to 18, SPID0-8: -8 to 24, SPID0-12: -12 to 36, SPID0-16: -16 to 48, SPID16-24: -8 to 24. The positive SPID value indicates improvement of pain relief. The higher the SPID value, the more improvement of pain relief.

    Time frame: 0-6, 0-8, 0-12, 0-16 and 16-24 hours postdose

  2. Summed, Time-weighted Total Pain Relief Scores (TOTPARs)

    TOTPARs were derived by multiplying the pain relief score at each post-dose timepoint by the duration (in hours) since the preceding timepoint and then summing these values over the specified interval. Pain Relief was evaluated at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours postdose, using the 5-point overall pain relief scale: 0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief. The possible total score ranges of TOTPARs are: TOTPAR0-6: 0 to 18, TOTPAR0-8: 0 to 24, TOTPAR0-12: 0 to 36, TOTPAR0-16: 0 to 48, TOTPAR0-24: 0 to 72, TOTPAR16-24: 0 to 24.

    Time frame: 0-6, 0-8, 0-12, 0-16, 0-24, and 16-24 hours postdose

  3. Pain Intensity Differences (PIDs) by Time From Initial Dose

    Pain intensity was evaluated using a 4-point Categorical Pain Intensity Rating Scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe

    Time frame: At 0, 0.25, 0.5, 0.75, 1, 2, 3, 4 ,5 ,6, 8, 12, 16, 20 and 24 hours postdose

  4. Pain Relief From Initial Dose

    Pain Relief was evaluated using the 5-point overall pain relief scale: 0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief

    Time frame: At 0.25, 0.5, 0.75, 1, 2, 3, 4 ,5 ,6, 8, 12, 16, 20 and 24 hours postdose

  5. Median Time to First Intake of Rescue Medication

    Time to first use of rescue medication was estimated using Kaplan-Meier method and analyzed by a logrank test stratified by baseline pain intensity. If at least 50% of subjects in a treatment group took rescue medication, the median time to first rescue was determined for that treatment group.

    Time frame: Up to 24 hours postdose

  6. Cumulative Percentage of Participants Who Took Rescue Medication

    Time frame: At 0.25, 0.5, 0.75, 1, 2, 3, 4 ,5 ,6, 8, 12, 16, 20 and 24 hours postdose

  7. Number of Times the Participants Took Rescue Medication Over the 24-hour Period

    Time frame: 24 hours postdose

  8. Global Assessment of the Investigational Product as a Pain Reliever

    Global assessment of investigational product as a pain reliever was rated on a 5-point categorical scale: 0 = poor, 1 = fair, 2 = good, 3 = very good, 4 = excellent

    Time frame: 24 hours postdose or immediately before the first intake of rescue medication

07

Results

Posted May 7, 2013

Participant flow

Participant flow — Overall Study
MilestoneNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
Started12012060
Completed12012060
Not completed000

Outcome measures

PrimarySummed, Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24)

SPID0-24 was calculated by multiplying the pain intensity difference score at each post-dose timepoint by the duration (in hours) since the preceding timepoint and then summing these values over 0 to 24 hours. Pain intensity was measured at baseline, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours using the 4-point categorical pain intensity scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. SPID0-24 can vary from -24 to 72. The positive SPID value indicates improvement of pain relief. The higher the SPID value, the more improvement of pain relief.

Time frame:
From 0 to 24 hours post-dose
Reported as:
Mean · Score on the scale
Summed, Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24)
Score on the scaleNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
Summed, Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24)23.2 ± 2.0123.6 ± 2.01-0.6 ± 2.85
SecondarySummed, Time-weighted Pain Intensity Differences (SPID)

Pain intensity was measured at baseline, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours using the 4-point categorical pain intensity scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total possible score ranges of SPIDs are SPID0-6: -6 to 18, SPID0-8: -8 to 24, SPID0-12: -12 to 36, SPID0-16: -16 to 48, SPID16-24: -8 to 24. The positive SPID value indicates improvement of pain relief. The higher the SPID value, the more improvement of pain relief.

Time frame:
0-6, 0-8, 0-12, 0-16 and 16-24 hours postdose
Reported as:
Mean · Score on the scale
Summed, Time-weighted Pain Intensity Differences (SPID)
Score on the scaleNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
From 0 to 6 hours, LS Mean5.3 (4.5 to 6.7)5.3 (4.5 to 6.1)-0.5 (-1.6 to 0.7)
From 0 to 8 hours, LS Mean7.0 (5.9 to 8.1)6.9 (5.7 to 8.0)-0.8 (-2.3 to 0.8)
From 0 to 12 hours, LS Mean10.9 (9.1 to 12.7)10.9 (9.2 to 12.7)-0.9 (-3.4 to 1.6)
From 0 to 16 hours, LS Mean14.7 (12.3 to 17.2)15.0 (12.5 to 17.5)-1.0 (-4.5 to 2.6)
From 16 to 24 hours, LS Mean8.5 (6.9 to 10.0)8.6 (7.1 to 10.1)0.4 (-1.8 to 2.6)
SecondarySummed, Time-weighted Total Pain Relief Scores (TOTPARs)

TOTPARs were derived by multiplying the pain relief score at each post-dose timepoint by the duration (in hours) since the preceding timepoint and then summing these values over the specified interval. Pain Relief was evaluated at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours postdose, using the 5-point overall pain relief scale: 0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief. The possible total score ranges of TOTPARs are: TOTPAR0-6: 0 to 18, TOTPAR0-8: 0 to 24, TOTPAR0-12: 0 to 36, TOTPAR0-16: 0 to 48, TOTPAR0-24: 0 to 72, TOTPAR16-24: 0 to 24.

Time frame:
0-6, 0-8, 0-12, 0-16, 0-24, and 16-24 hours postdose
Reported as:
Mean · Score on the scale
Summed, Time-weighted Total Pain Relief Scores (TOTPARs)
Score on the scaleNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
From 0 to 6 hours13.1 (11.9 to 14.3)12.8 (11.6 to 14.0)4.7 (2.9 to 6.4)
From 0 to 8 hours17.4 (15.7 to 19.1)16.8 (15.1 to 18.5)6.1 (3.8 to 8.5)
From 0 to 12 hours26.5 (23.9 to 29.2)26.4 (23.7 to 29.0)9.7 (5.9 to 13.5)
From 0 to 16 hours35.5 (31.8 to 39.2)35.8 (32.0 to 39.5)13.4 (8.1 to 18.6)
From 0 to 24 hours54.5 (48.6 to 60.4)55.1 (49.2 to 61.0)21.8 (13.4 to 30.2)
From 16 to 24 hours19.0 (16.7 to 21.3)19.4 (17.1 to 21.6)8.4 (5.2 to 11.6)
SecondaryPain Intensity Differences (PIDs) by Time From Initial Dose

Pain intensity was evaluated using a 4-point Categorical Pain Intensity Rating Scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe

Time frame:
At 0, 0.25, 0.5, 0.75, 1, 2, 3, 4 ,5 ,6, 8, 12, 16, 20 and 24 hours postdose
Reported as:
Mean · Score on the scale
Pain Intensity Differences (PIDs) by Time From Initial Dose
Score on the scaleNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
0.25 hours, LS Mean1.9 (1.8 to 2.0)2.0 (1.9 to 2.1)2.0 (1.9 to 2.2)
0.5 hours, LS Mean1.7 (1.6 to 1.8)1.7 (1.6 to 1.8)1.9 (1.8 to 2.1)
0.75 hours, LS Mean1.4 (1.3 to 1.6)1.5 (1.4 to 1.6)2.0 (1.8 to 2.2)
1 hours, LS Mean1.2 (1.1 to 1.4)1.4 (1.3 to 1.5)2.1 (1.9 to 2.3)
2 hours, LS Mean1.2 (1.1 to 1.4)1.2 (1.0 to 1.3)2.3 (2.1 to 2.5)
3 hours, LS Mean1.2 (1.1 to 1.4)1.2 (1.0 to 1.3)2.3 (2.1 to 2.6)
4 hours, LS Mean1.2 (1.0 to 1.3)1.2 (1.1 to 1.4)2.3 (2.1 to 2.5)
5 hours, LS Mean1.3 (1.1 to 1.4)1.2 (1.1 to 1.4)2.3 (2.1 to 2.5)
6 hours, LS Mean1.3 (1.1 to 1.4)1.3 (1.1 to 1.4)2.3 (2.1 to 2.5)
8 hours, LS Mean1.3 (1.2 to 1.5)1.4 (1.2 to 1.6)2.3 (2.1 to 2.6)
12 hours, LS Mean1.2 (1.0 to 1.4)1.2 (1.0 to 1.3)2.2 (2.0 to 2.5)
16 hours, LS Mean1.2 (1.0 to 1.4)1.2 (1.0 to 1.4)2.2 (1.9 to 2.5)
20 hours, LS Mean1.2 (1.0 to 1.4)1.1 (1.0 to 1.3)2.2 (1.9 to 2.5)
24 hours, LS Mean1.1 (0.9 to 1.3)1.1 (0.9 to 1.3)2.1 (1.8 to 2.3)
SecondaryPain Relief From Initial Dose

Pain Relief was evaluated using the 5-point overall pain relief scale: 0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief

Time frame:
At 0.25, 0.5, 0.75, 1, 2, 3, 4 ,5 ,6, 8, 12, 16, 20 and 24 hours postdose
Reported as:
Mean · Score on the scale
Pain Relief From Initial Dose
Score on the scaleNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
0.25 hours0.9 ± 0.960.8 ± 0.920.6 ± 0.75
0.5 hours1.5 ± 1.081.3 ± 1.020.8 ± 0.94
0.75 hours2.0 ± 1.211.7 ± 1.140.9 ± 0.96
1 hour2.2 ± 1.292.0 ± 1.170.9 ± 1.02
2 hours2.3 ± 1.302.3 ± 1.290.8 ± 1.02
3 hours2.3 ± 1.332.4 ± 1.390.7 ± 1.03
4 hours2.4 ± 1.412.2 ± 1.430.9 ± 1.20
5 hours2.3 ± 1.352.2 ± 1.490.9 ± 1.23
6 hours2.2 ± 1.372.2 ± 1.530.8 ± 1.28
8 hours2.1 ± 1.402.0 ± 1.500.8 ± 1.23
12 hours2.3 ± 1.512.4 ± 1.570.9 ± 1.46
16 hours2.2 ± 1.522.3 ± 1.611.0 ± 1.47
20 hours2.3 ± 1.582.3 ± 1.631.0 ± 1.50
24 hours2.4 ± 1.632.5 ± 1.681.2 ± 1.73
SecondaryMedian Time to First Intake of Rescue Medication

Time to first use of rescue medication was estimated using Kaplan-Meier method and analyzed by a logrank test stratified by baseline pain intensity. If at least 50% of subjects in a treatment group took rescue medication, the median time to first rescue was determined for that treatment group.

Time frame:
Up to 24 hours postdose
Reported as:
Median · Hours
Median Time to First Intake of Rescue Medication
HoursNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
Median Time to First Intake of Rescue MedicationNA (NA to NA)NA (NA to NA)2.9 (1 to 12)
SecondaryCumulative Percentage of Participants Who Took Rescue Medication
Time frame:
At 0.25, 0.5, 0.75, 1, 2, 3, 4 ,5 ,6, 8, 12, 16, 20 and 24 hours postdose
Reported as:
Number · Percentage of participants
Cumulative Percentage of Participants Who Took Rescue Medication
Percentage of participantsNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
0.25 hours000
0.5 hours0.00.00.0
0.75 hours0.00.00.0
1 hour0.00.00.0
2 hours7.57.530.0
3 hours12.513.350.0
4 hours16.716.755.0
5 hours18.320.058.3
6 hours20.023.360.0
8 hours20.825.063.3
12 hours22.525.866.7
16 hours25.027.566.7
20 hours26.727.566.7
24 hours26.727.566.7
SecondaryNumber of Times the Participants Took Rescue Medication Over the 24-hour Period
Time frame:
24 hours postdose
Reported as:
Mean · Rescue medication intakes
Number of Times the Participants Took Rescue Medication Over the 24-hour Period
Rescue medication intakesNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
Number of Times the Participants Took Rescue Medication Over the 24-hour Period0.5 ± 0.860.6 ± 1.021.4 ± 1.20
SecondaryGlobal Assessment of the Investigational Product as a Pain Reliever

Global assessment of investigational product as a pain reliever was rated on a 5-point categorical scale: 0 = poor, 1 = fair, 2 = good, 3 = very good, 4 = excellent

Time frame:
24 hours postdose or immediately before the first intake of rescue medication
Reported as:
Number · Participants
Global Assessment of the Investigational Product as a Pain Reliever
ParticipantsNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
0 - Poor161834
1 - Fair14125
2 - Good22205
3 - Very good334312
4 - Excellent35274

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium ER (BAYH6689)—0/120 (0%)28/120 (23.3%)
Naproxen Sodium IR (Aleve, BAYH6689)—0/120 (0%)36/120 (30%)
Placebo—0/60 (0%)23/60 (38.3%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventNaproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)Placebo
HeadacheNervous system disorders11/12014/12012/60
NauseaGastrointestinal disorders10/1209/1208/60
DizzinessNervous system disorders2/1206/1202/60
HypoaesthesiaNervous system disorders2/1204/1203/60
VomitingGastrointestinal disorders4/1203/1202/60
AlveolitisRespiratory, thoracic and mediastinal disorders1/1203/1202/60
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders1/1201/1202/60
Ear painEar and labyrinth disorders1/1202/1200/60
Paraesthesia oralGastrointestinal disorders0/1200/1201/60
Feeling hotGeneral disorders0/1202/1200/60

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Naproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)PlaceboTotal
Mean24.0 ± 5.0523.0 ± 4.6725.0 ± 6.5623.8 ± 5.28
Sex: Female, Male
Sex: Female, Male(Participants)Naproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)PlaceboTotal
Female707141182
Male504919118
Pain Intensity Score
Pain Intensity Score(Participants)Naproxen Sodium ER (BAYH6689)Naproxen Sodium IR (Aleve, BAYH6689)PlaceboTotal
0 = None0000
1 = Mild0000
2 = Moderate969753246
3 = Severe2423754
08

Study locations

1 site
  • Austin, Texas 78744, United States
09

References and documents

Publications

  • Laurora I, An R. Efficacy of single-dose, extended-release naproxen sodium 660 mg in postsurgical dental pain: two double-blind, randomized, placebo-controlled trials. Curr Med Res Opin. 2016;32(2):331-42. doi: 10.1185/03007995.2015.1123680. Epub 2015 Dec 15. Erratum In: Curr Med Res Opin. 2016;32(3):611. doi: 10.1185/03007995.2016.1148233. PubMed 26588111 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2011
First posted
Jul 8, 2011
Start
Jun 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
May 7, 2013
Last update
Aug 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01389284
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 8, 2011
Start date
Jun 2011
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
May 7, 2013
Last update
Aug 25, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion